Alendronate and naproxen are synergistic for development of gastric ulcers

Archives of Internal Medicine

Volumn 161, Issue 1, 2001, Pages 107-110

  Graham, David Y ^a,b   Malaty, Hoda M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; NAPROXEN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; ENDOSCOPY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH MUCOSA; STOMACH ULCER; TREATMENT PLANNING;

EID: 0035825315     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.161.1.107     Document Type: Article

References (33)

1. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone
2. Alendronate-induced ulcerative esophagitis
3. Esophagitis associated with the use of alendronate
4. Improper alendronate administration and a case of pill esophagitis
5. Oesophageal stricture associated with alendronic acid
6. Esophagitis and alendronate
7. "Pill esophagitis" - The case of alendronate
8. Multiple ulcerative esophagitis caused by alendronate
9. Esophagitis associated with alendronate sodium
10. Esophageal stricture associated with alendronate therapy
11. A new probable increasing cause of esophageal ulceration: Alendronate
12. Incidence of gastrointestinal side effects due to alendronate is high in clinical practice
13. Pamidronate: An unrecognized problem in gastrointestinal tolerability
14. Alendronate-associated esophagitis: Endoscopic and pathologic features
15. Alendronate-associated esophageal injury: Pathologic and endoscopic features
16. Primary amino-bisphosphonates: A new class of gastrotoxic drugs: Comparison of alendronate and aspirin
17. Effects of alendronate on gastric and duodenal mucosa
18. Effects of alendronate on gastric and duodenal mucosa
19. Excess gastric ulcers are associated with alendronate therapy
20. Alendronate gastric ulcers
21. Effects of treatment with bisphosphonates on gastrointestinal and esophageal mucosa in patients with osteoporosis: Pamidronate versus alendronate
22. 2): Results of a randomized controlled trial
23. Upper gastrointestinal toxicity of alendronate
24. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: Where we stand
25. Effect of Helicobacter pylori infection on the severity of gastroduodenal mucosal injury after the acute administration of naproxen or aspirin to normal volunteers
26. Endoscopic comparison of cimetidine and sucralfate for prevention of naproxen-induced acute gastroduodenal injury: Effect of scoring method
27. Effectiveness and tolerance of "solid vs. liquid" potassium replacement therapy: Arrhythmias, myocardial infarction, and hypertension
28. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis
29. Nonclinical model for assessing gastric effects of bisphosphonates
30. Oral bisphosphonates in the treatment of osteoporosis: A review
31. Effects of two oral doses of alendronate in the treatment of Paget's disease of bone
32. A randomized double-blind, placebo-controlled endoscopic study comparing the effects of alendronate and risedronate on upper gastrointestinal mucosae
33. Upper gastrointestinal tract safety profile of alendronate: The Fracture Intervention Trial